NYSE$ABT
Abbott Laboratories · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Abbott reported Q1 2025 sales of $10.36B with net earnings of $1.33B and diluted EPS of $0.76.
Sales were $10.36 billion for the quarter ended March 31, 2025, with growth across established pharmaceuticals, nutrition, diagnostics, and medical devices. Net earnings were $1.33 billion ($0.76 diluted EPS). FX and emerging-market demand are discussed in segment commentary.
- Q1 sales $10.36B.
- Net earnings $1.33B; diluted EPS $0.76.
- Medical devices and diagnostics support diversified growth.
- Currency and China diagnostics demand affect comparability.
Headline financials
Revenue & EPS history
Abbott · Revenue · Quarterly
$10.4B
Revenue by segment
Abbott · $6.7B total across 2 segments · Q3 2023
- Medical Devices$4.25B+17.5%63.4%
- Diagnostics$2.45B-33.3%36.6%
Forward guidance
The quarterly filing discusses operating priorities, liquidity, and sector risks.
Tailwinds
- MD&A outlines strategic priorities and capital allocation.
- Segment commentary supports the earnings narrative.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items can affect year-over-year comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+0.6%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+1.1%
Avg return
30 days after
61%
45 / 74 earnings
Positive
+10.3%
Q3 2013
Best reaction
-9.9%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | -8.7% | -16.8% | |
| Q4 2025 | -9.9% | -10.3% | -7.1% | |
| Q3 2025 | -2.9% | -2.8% | -2.0% | |
| Q2 2025 | -0.1% | +1.4% | +3.3% | |
| Q1 2025 | +2.8% | +2.9% | +6.8% | |
| Q4 2024 | +0.8% | +10.8% | +15.5% | |
| Q3 2024 | +1.6% | +0.8% | -0.1% | |
| Q2 2024 | -2.5% | -0.7% | +6.0% | |
| Q1 2024 | -3.6% | -2.0% | -4.7% | |
| Q4 2023 | -1.4% | -0.5% | +4.8% | |
| Q3 2023 | +3.6% | +4.0% | +8.0% | |
| Q2 2023 | +6.5% | +5.3% | -3.3% | |
| Q1 2023 | +6.0% | +6.0% | +4.6% | |
| Q4 2022 | -1.3% | -2.4% | -10.7% | |
| Q3 2022 | -9.3% | -6.4% | -1.1% | |
| Q2 2022 | +0.7% | -1.3% | +0.1% | |
| Q1 2022 | +2.8% | +0.0% | -5.6% | |
| Q4 2021 | -2.3% | +3.4% | -0.7% | |
| Q3 2021 | +4.8% | +6.1% | +6.3% | |
| Q2 2021 | +1.5% | +0.7% | +6.2% | |
| Q1 2021 | -1.5% | -1.0% | -5.4% | |
| Q4 2020 | +4.9% | +6.8% | +4.4% | |
| Q3 2020 | +1.0% | +0.6% | +2.3% | |
| Q2 2020 | +2.6% | +1.5% | +3.4% | |
| Q1 2020 | +5.6% | +3.4% | -1.2% | |
| Q4 2019 | +1.1% | -0.2% | -2.5% | |
| Q3 2019 | +0.5% | -0.4% | +4.5% | |
| Q2 2019 | +5.5% | +5.9% | +1.9% | |
| Q1 2019 | -3.2% | -2.4% | -0.5% | |
| Q4 2018 | -0.9% | -3.4% | +6.5% | |
| Q3 2018 | -4.0% | -3.4% | +1.5% | |
| Q2 2018 | +1.6% | +0.6% | +3.1% | |
| Q1 2018 | +0.1% | -1.6% | +3.2% | |
| Q4 2017 | +6.7% | +6.9% | +0.8% | |
| Q3 2017 | +1.7% | +1.9% | +0.9% | |
| Q2 2017 | +2.9% | +2.8% | -1.4% | |
| Q1 2017 | +1.3% | +1.6% | -0.6% | |
| Q4 2016 | +1.6% | +1.6% | +12.5% | |
| Q3 2016 | -1.0% | -1.8% | -3.2% | |
| Q2 2016 | +3.0% | +3.9% | +5.8% | |
| Q1 2016 | +0.1% | — | — | |
| Q4 2015 | -6.5% | — | — | |
| Q3 2015 | +4.2% | — | — | |
| Q2 2015 | +2.9% | — | — | |
| Q1 2015 | +2.8% | — | — | |
| Q4 2014 | +3.1% | — | — | |
| Q3 2014 | +0.1% | — | — | |
| Q2 2014 | +1.8% | — | — | |
| Q1 2014 | +2.5% | — | — | |
| Q4 2013 | -4.3% | — | — | |
| Q3 2013 | +10.3% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +1.3% | — | — | |
| Q4 2012 | -0.3% | — | — | |
| Q3 2012 | -7.6% | — | — | |
| Q2 2012 | -1.0% | — | — | |
| Q1 2012 | -1.5% | — | — | |
| Q4 2011 | -0.2% | — | — | |
| Q3 2011 | -0.4% | — | — | |
| Q2 2011 | -0.1% | — | — | |
| Q1 2011 | +0.9% | — | — | |
| Q1 2008 | +1.4% | — | — | |
| Q4 2010 | +1.4% | — | — | |
| Q3 2010 | -0.8% | — | — | |
| Q2 2010 | +0.7% | — | — | |
| Q1 2009 | -1.4% | — | — | |
| Q1 2010 | +0.9% | — | — | |
| Q4 2007 | -1.1% | — | — | |
| Q4 2009 | -1.1% | — | — | |
| Q3 2008 | +1.4% | — | — | |
| Q3 2009 | +1.4% | — | — | |
| Q2 2009 | +2.1% | — | — | |
| Q4 2008 | +2.1% | — | — | |
| Q2 2008 | +2.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro